The recent identification of the CARD15
Introduction
The current hypothesis for the pathogenesis of chronic inflammatory bowel disease comprises a loss of tolerance towards luminal antigens in a genetically susceptible host resulting in a chronic, spontaneously relapsing inflammation.
Several lines of evidence are compatible with a significant role of genetic factors in inflammatory bowel disease, especially in Crohn's disease. The most striking example is provided by twin studies, which report concordance rates for Crohn's disease between 42 and 58% in monozygotic twins [1] [2] [3] [4] , whereas in dizygotic twins concordance is not significantly enhanced. Epidemiological studies demonstrate a familial aggregation with approximately 5-10% of all affected individuals reporting a positive familial history of inflammatory bowel disease [5] [6] [7] . The relative risk for first degree relatives of patients with Crohn's disease is estimated to be about 15-fold increased when compared to the general population [8, 9] . Ethnic differences in the prevalence of the disease further underline the significant role of genetic susceptibility. The highest prevalence rates are reported for Ashkenazi Jews. In African-Americans the rates are lower than in Caucasians, and in Asians the lowest rates have been observed [10] [11] [12] [13] [14] [15] .
For several years, considerable efforts aimed at the identification of the genetic background of inflammatory 
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Gly908Arg 1007fs 1 28 bowel disease. Two complementary approaches, namely genetic linkage analysis and the search for candidate genes, led to the identification of a number of susceptibility loci and to the postulation of functional candidate genes with a presumptive role in immune regulation. The first real breakthrough, however, was achieved only two years ago with the identification of the CARD15/NOD2 gene as the first susceptibility gene with a consistent association with Crohn's disease.
Alterations of the CARD15/NOD2 Gene and Crohn's Disease
In May 2001, two research groups reported independently that Crohn's disease is associated with mutations in the NOD2 gene, which was later renamed CARD15 [16, 17] . This association has been confirmed by numerous other studies [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] .
The CARD15 gene is located in the pericentromeric region of chromosome 16 inside the susceptibility locus displaying the strongest linkage with Crohn's disease [29, 30] , namely the IBD1 locus. It encodes a 1,040-aminoacid protein containing several functional domains: two N-terminal caspase activation and recruitment domains (CARDs), a centrally located nucleotide binding domain (NBD) and a C-terminal leucine-rich repeat domain (LRR) ( fig. 1) [31] . Functional studies demonstrated that CARD15 is one of the numerous pattern-recognition receptors implicated in the intracellular sensing of bacterial components [31] .
Crohn's Disease-Associated CARD15 Genetic Variants Three common variants of CARD15 have been linked to the development of Crohn's disease. The most common genetic defect is the frameshift mutation 1007fs (3020insC) in exon 11, resulting in a premature stop codon and thus in a truncated CARD15 protein. The two other missense mutations are located in exons 4 and 8 and lead to amino acid substitutions Arg702Trp and Gly908Arg, respectively. These three mutations are located in the leucine-rich repeat domain of the CARD15 protein or in its vicinity ( fig. 1 ) and occur on the background of the most common variant Pro268Ser.
Approximately 30% of Crohn's disease patients carry one and up to 17% carry two mutated CARD15/NOD2 risk alleles [32] . The allele frequencies reported for Crohn's disease and control populations in a variety of studies are depicted in table 1. The three above mentioned CARD15 variants seem to confer an increased risk for Crohn's disease only in Caucasians, as these mutations were not detected in populations with a different ethnic background, e.g. in Japanese [33] [34] [35] , Korean [36] or Chinese [37] . A study in African-Americans with Crohn's disease also reported lower carriage rates of these alleles and the presence of uncommon variants such as Arg790Gln [38] . Among Caucasians, ethnic differences in the allele frequencies have also been reported. Jewish patients have a higher frequency of the Gly908Arg allele and a lower frequency of the Arg702Trp allele, when compared to non-Jewish Crohn's disease patients [26] . The allele frequencies in familial and sporadic Crohn's disease were comparable in two Caucasian cohorts [19, 24] , whereas in a population of Ashkenazi Jews, familial cases displayed a significantly higher frequency of the Gly908Arg variant than sporadic cases [39] .
Having one copy of a mutated CARD15/NOD2 allele confers a 2-to 4-fold increased risk of developing Crohn's disease, whereas having two mutated copies in homozygous or compound heterozygous form increases the risk 20-to 40-fold [16] [17] [18] . However, homozygosity for mutant CARD15/NOD2 has also been observed in healthy (5) controls [40] . These data suggest that loss-of-function mutations in the CARD15/NOD2 gene are neither necessary nor sufficient for developing Crohn's disease, and that other genetic factors as well as environmental influences are needed for disease manifestation.
Role of CARD15: Link between Genetic Susceptibility and Environmental Factors (e.g. Bacterial Flora)
The CARD15 protein is located in the cytosol and is now recognized as a member of a family of proteins which are involved in intracellular recognition of bacterial components ( fig. 2) [41] [42] . Although the expression of CARD15 was reported to be restricted to peripheral blood monocytes [31] , recent studies have shown basic expression in granulocytes and dendritic cells [43] as well as in several colonic epithelial cell lines and primary intestinal epithelial cells [44] . Moreover, elevated amounts of CARD15 were found in primary colonic epithelial cells [45, 46] and in particular in Paneth cells [47] from patients with inflammatory bowel disease. The expression of CARD15 can be enhanced by proinflammatory cytokines and bacterial components via Nuclear Factor (NF)-ÎB activation [43, 45] .
Functional studies in human embryonic kidney (HEK) 293T cells transfected with CARD15 revealed that the wild-type protein mediates responsiveness to lipopolysaccharide (LPS) and peptidoglycan (PGN) preparations from several bacteria [17, 26, 31, 48] . Recent works identified muramyl dipeptide (MDP), the minimal essential structure of bacterial peptidoglycan, as the moiety specifically recognised by CARD15 [49, 50] . The three major Crohn's disease-associated variants are defective in their ability to activate NF-ÎB in response to MDP [17, 26] . Especially the truncated CARD15 protein, which arises from the 1007fs mutation, completely lacks this activity [17, 49, 50] . These results were obtained in transfected cells and were subsequently verified by assessment of mRNA expression and protein synthesis of pro-and antiinflammatory cytokines in peripheral blood monocytes from individuals carrying different CARD15 variants [49, Török et al., unpubl. data] .
At present, it is not clear how CARD15/NOD2 mutations and the ensuing decreased NF-ÎB activation confer susceptibility to Crohn's disease. Assuming that CARD15 is a pattern-recognition receptor, it seems possible that the mutations result in an inadequate innate immune response, e.g. a defective activation of monocytes-macrophages in response to intestinal microbes. This disturbed response could be associated with impaired killing of intracellular microbes resulting in compensatory increase of other components of the immune system such as a marked effector T cell response [51] . On the other hand, the absence of functional CARD15 in epithelial cells could lead to an impaired secretion of chemokines and defensins in response to microbial products followed by a proliferation of bacteria in the crypts and a loss of barrier function of the mucosa. Several observations support this hypotheses. Hisamatsu et al. [44] showed that CARD15 functions as an antibacterial factor in human intestinal epithelial cells by constraining intracellular bacterial survival and that the 1007fs mutant lacks this activity. Moreover, a recent communication by Wehkamp et al. [52] reported an impaired expression of antibacterial peptides (defensins) in epithelial cells from Crohn's disease patients carrying CARD15/NOD2 mutations.
The identification of CARD15/NOD2 as a susceptibility locus for Crohn's disease confirms at the molecular level that an inappropriate activation of the mucosal immune system by the intestinal flora plays a causal role in the development of Crohn's disease. Thus, this association confers an important link between inflammatory bowel disease and innate immunity [53] .
Clinical Implications
Among the cases classified as Crohn's disease, different clinical phenotypes with regard to disease location, extent, aggressiveness, behavior, local and systemic complications as well as varying responses to medical therapy have been described [54] . The observation of conserved phenotypes in multiplex Crohn's disease families [55, 56] is compatible with the assumption that the genetic background influences the phenotype.
Following the identification of CARD15/NOD2 as a susceptibility gene for Crohn's disease, many questions were raised regarding the importance of this discovery for the daily clinical practice. Could mutations in this gene determine the natural history of Crohn's disease? Is the CARD15/NOD2 genotype associated with a specific phenotype, a specific location, extent or aggressiveness of the disease? Can it predict the response to a specific therapeutic agent? Is there a diagnostic role for the mutations? Should we perform screening for CARD15/NOD2 mutants in the general population, in the groups at risk, or in Crohn's disease patients before initiating a specific therapy? Only a few of these questions can be answered satisfactorily at present.
CARD15/NOD2 Genotype and Clinical Course of Crohn's Disease
Several studies about the relationship between CARD15/NOD2 mutations and the clinical presentation of Crohn's disease have been published. The only consistent finding concerns the disease location, as a number of studies reported a significant association between carriage of one or more CARD15/NOD2 risk alleles and ileal disease. Ahmad and colleagues [20] performed genotypephenotype analysis in 244 extensively characterized Crohn's disease patients with a median follow-up of 16 years. The results demonstrated that CARD15/NOD2 mutations determine ileal disease. Among 429 patients analyzed in a large European study, the frequency of CARD15 mutations was significantly increased in ileumspecific disease, when compared with colon-specific disease (26.9 vs. 12.7%, p = 0.0004) [21] . In a French study comprising 166 sporadic and 287 familial cases of Crohn's disease, the patients carrying two risk alleles were characterized by a less frequent colonic involvement than wild-type patients (p = 0.003) [19] . The predominance of ileal disease in patients carrying mutations in CARD15 was also reported in other studies [24, 57, 58] . Importantly, the association with disease location (ileal and right colonic disease) was the only one also confirmed in a prospective cohort study, in which 106 German and 55 Norwegian patients with Crohn's disease were enrolled [57] .
Data concerning disease behavior are more inconsistent. Reasons could be the use of different definitions for the classification as well as the fact that disease behavior changes through time, which underscores the need for long observation periods and illustrates the inherent difficulties of retrospectively differentiating clinical subtypes. Some groups reported an association with the fibrostenotic phenotype [19, 25, [57] [58] [59] , the presence of fistulas [25, [57] [58] [59] or the need for surgery [25, 58] , whereas others did not confirm such findings [20, 60] .
An earlier age of disease onset in patients carrying two CARD15/NOD2 risk alleles in homozygous or compound heterozygous form has also been reported [19, 20, 61] . Onset of disease occurred approximately 2 years earlier in these patients, when compared with all Crohn's disease patients.
CARD15 and Response to Treatment
At this time little is known about the influence of CARD15 genotype on the response to medical therapy in Crohn's disease. Vermeire et al. [62] studied the CARD15/NOD2 genotype in 245 patients with Crohn's disease receiving therapy with anti TNF-alpha antibodies (infliximab) and observed no relationship between the presence of mutations and short-term response or response duration. Moreover, the authors could not identify any clinical characteristic which, in combination with CARD15/NOD2 mutations, modified the response to treatment. Similarly, Mascheretti et al. [63] reported no association between the response to infliximab and the CARD15 variants in two independent cohorts of 90 and 444 patients with Crohn's disease. These negative findings exclude the three CARD15 mutants as a predictive factor for therapeutic response to infliximab. However, data concerning other therapeutic approaches, such as glucocorticoids, aminosalicylates or immunosuppressors, are lacking so far.
Screening for CARD15/NOD2 Variants?
One of the major questions raised is whether screening for CARD15/NOD2 genotype in the population at risk or in patients already diagnosed with Crohn's disease should be introduced into the clinical practice.
Giving the limited penetrance and the lack of consistent information about the positive and negative predictive values of genotypes in unaffected relatives (the major risk group), a screening for CARD15/NOD2 variants is currently not recommended. The majority of high-risk individuals will not develop Crohn's disease, as studies in twin siblings demonstrated [64] . Moreover, even if highrisk individuals are detected by genotyping, there are at present no efficient prophylactic methods that could prevent disease onset. Thus, the diagnostic role of CARD15/ NOD2 genotyping is limited. It was suggested that mutation analysis will help to classify undifferentiated colitis cases. However, the low frequency of CARD15/NOD2 mutations in Crohn's disease patients with an ulcerative colitis-like phenotype limits this clinical application [53] .
Recommending genotyping in patients already diagnosed with Crohn's disease is also premature. Data about the influence of the genotype on disease behavior are inconsistent and large prospective studies are needed to determine whether mutations in CARD15/NOD2 can predict the prognosis of Crohn's disease, e.g. a more aggressive disease course with need of early immunosuppressive therapy.
In addition, the lack of data regarding the association between CARD15 variants and specific therapeutic responses currently disables the possibility of individualised, genotype-based therapies.
Conclusions
The association of CARD15/NOD2 mutations with Crohn's disease opens up a new era in the history of inflammatory bowel disease. It shows how the two complementary approaches, linkage analysis and the study of candidate genes can be successfully used in the identification of disease susceptibility genes. The role of CARD15 as a pattern recognition receptor and the loss of function of the genetic variants associated with Crohn's disease establishes a link between innate immunity and chronic bowel inflammation and confirms the pathogenetic importance of luminal bacteria. Moreover, these data are compatible with an immunodeficiency of the mucosal immune system as a pivotal first step in the pathogenesis of Crohn's disease [65] . Although the discoveries are important for understanding the etiology of Crohn's disease, at this time, they have only a modest role in clinical practice. Further studies are needed to clarify the genotype-phenotype relationships and the role of genetic testing in predicting disease behavior. A better understanding of the pathophysiologic mechanisms could lead to the development of new prophylactic and therapeutic strategies and to an individualized manner of their application. In case these prophylactic and therapeutic goals are reached, genetic testing for identifying high risk individuals and for predicting response to specific therapies will constitute an important new diagnostic tool for clinicians.
